Citicoline (CDP-Choline) and Concentration: What Does the Research Actually Show?

Citicoline (CDP-choline, cytidine-5'-diphosphocholine) is a compound that occurs naturally in the body as an intermediate in the production of phosphatidylcholine — the main phospholipid of neuronal cell membranes. We've covered the compound's full profile, its history of medical use after stroke, and its mechanism in detail in our knowledge-base entry on citicoline — here we focus exclusively on one specific question: what the evidence says about citicoline's effect on concentration, attention, and reaction speed in healthy people, not its full supplementation profile.

This distinction matters, because marketing for citicoline supplements often blends together different, not equally well-documented domains — memory in older adults, concentration in healthy young people, mood, and even recovery after brain injury — as if it were one uniform effect. In reality, the evidence varies in strength and quality depending on which of these domains it concerns. The most consistent and reproducible signal concerns precisely attention and psychomotor speed — and that's what this article is about.

Once absorbed, citicoline is broken down into choline and cytidine, which are resynthesized inside neurons after crossing the blood-brain barrier. The choline released in this process is a direct precursor of acetylcholine — a neurotransmitter that plays a key role not only in long-term memory, but above all in attention systems: cortical arousal networks, the speed of stimulus processing, and the ability to sustain focus on a task over time (so-called sustained attention).

This distinguishes the theoretical basis for an effect on concentration from an effect on long-term memory, which is tied more to the structural integrity of hippocampal neuron membranes (built from phosphatidylcholine) than to the moment-to-moment availability of acetylcholine at the synapse. In other words — it's mechanistically plausible that citicoline could affect attention faster and more noticeably than memory, since the acetylcholine pathway operates on a scale of minutes to hours, while remodeling neuronal membranes is a process of weeks.

This is one of the most frequently cited studies in discussions of citicoline and concentration, because — unlike many earlier citicoline studies — it involved a healthy, young population rather than stroke or dementia patients. The dose-response relationship (a stronger effect at a higher dose per kilogram of body weight) is an additional argument that the observed effect is a genuine biological signal rather than a statistical fluke.

In our knowledge-base entry on citicoline, we describe a separate study — Nakazaki et al. (2021, The Journal of Nutrition) — in which 500 mg of citicoline daily for 12 weeks improved overall memory performance, particularly episodic memory, in older adults with age-related memory decline. That's an important study, but it answers a different question than concentration in a younger, healthy population — a different target mechanism (membrane remodeling in the hippocampus), a different age group, and a different endpoint.

The large majority of newer clinical studies on citicoline in the context of concentration and attention in healthy people — including both studies discussed above — use a patented, standardized form of sodium citicoline sold under the trade name Cognizin®. Studies on patented ingredients are sometimes funded or co-run by the manufacturer or affiliated parties, which doesn't in itself invalidate the results — the methodology (randomization, blinding, control group) in both studies described here is solid — but it's a circumstance worth knowing when interpreting how many independent, industry-unaffiliated replications of a given result actually exist.

Worth emphasizing: none of the studies described evaluated citicoline in people with clinically diagnosed ADHD or other attention disorders — both study populations (teenagers in the McGlade study and adults in the Bruce study) were healthy. Extrapolating these results to clinical populations isn't warranted without separate studies in that specific group.

Citicoline has a well-documented safety profile thanks to decades of clinical use, mainly in the context of neurological rehabilitation after stroke, where doses were considerably higher than in supplementation. Studies on concentration in healthy people used doses of 250-500 mg daily — consistent with the typical range found in supplements on the market.

Among the many nootropics sold with a promise of improved concentration, citicoline is one of those with relatively more solid, though still moderate, research support — a randomized trial in healthy teenagers showed a consistent, statistically significant, dose-dependent effect on attention. That's more than can be said for many popular nootropics sold on the strength of a purely theoretical mechanism.

At the same time, it's worth keeping proportions in mind: this is a subtle effect, studied mainly in research linked to the manufacturer of a patented form, in a narrow, healthy population. People expecting a dramatic improvement in focus will likely be disappointed — people looking for mild, well-tolerated attention support have a more solid basis than with many competing supplements.